Zobrazeno 1 - 10
of 18
pro vyhledávání: '"J P Seenan"'
Autor:
V Svolos, R Hansen, R K Russell, D R Gaya, J P Seenan, J Macdonald, D Wilson, P Henderson, S Din, G T Ho, C Quince, U Z Ijaz, S Milling, B Nichols, R Papadopoulou, S McKirdy, L Gervais, S Shields, K Gerasimidis
Publikováno v:
Journal of Crohn's and Colitis. 17:i513-i515
Background Treatment with the CD-TREAT solid food diet improves disease activity indices, faecal calprotectin (FCAL) levels and quality of life in adults and children with active Crohn’s disease (CD); particularly in patients who adhere to the diet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eab0b656c79bc9f17acb1d6efb9b9ef4
https://doi.org/10.1093/ecco-jcc/jjac190.0510
https://doi.org/10.1093/ecco-jcc/jjac190.0510
Autor:
A Jatkowska, B White, B Nichols, V Svolos, K Gkikas, R Hansen, R K Russell, D Gaya, E Brownson, J P Seenan, S Milling, J MacDonald, K Gerasimidis
Publikováno v:
Journal of Crohn's and Colitis. 17:i937-i938
Background Treatment adherence is key to the efficacy of exclusive enteral nutrition (100% EN) in active Crohn’s disease (CD), but there are currently no biomarkers to objectively support this. We explored faecal parameters as putative biomarkers o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::078f8e1db626f0e64c5f30d07c78b546
https://doi.org/10.1093/ecco-jcc/jjac190.0934
https://doi.org/10.1093/ecco-jcc/jjac190.0934
Autor:
R Panaccione, G D'Haens, J P Seenan, F Caprioli, C Siegel, M Nakamura, S C Wei, K Kligys, Y Zhang, J Zambrano, A P Song, M Ferrante
Publikováno v:
Journal of Crohn's and Colitis. 17:i560-i560
Background Risankizumab (RZB), a p19-anti-interleukin-23 monoclonal antibody, has demonstrated efficacy as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (CD). This post hoc analysis evaluates the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f710fa2d4d53070f3fd01b8ccffecea0
https://doi.org/10.1093/ecco-jcc/jjac190.0563
https://doi.org/10.1093/ecco-jcc/jjac190.0563
Autor:
A Jatkowska, B White, P Jaskolski, E Brownson, J Clowe, J P Seenan, K Gerasimidis, J MacDonald
Publikováno v:
Journal of Crohn's and Colitis. 17:i833-i833
Background Exclusive enteral nutrition (EEN) and partial enteral nutrition (PEN), replacing at least 50% of the energy intake with formula, remain the only evidence-based dietary therapies in the management of Crohn’s disease (CD). Nonetheless, eme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f40798a972cb84015f7363353f0e1ba
https://doi.org/10.1093/ecco-jcc/jjac190.0830
https://doi.org/10.1093/ecco-jcc/jjac190.0830
P705 Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
Publikováno v:
Journal of Crohn's and Colitis. 17:i837-i837
Background Intravenous (IV) infliximab (IFX) monotherapy is associated with significant loss of response. Therapeutic drug monitoring shows an association with low serum trough drug levels and development of anti-IFX antibodies. Combination therapy w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaa25ad39f1f093d1d1544ea3bd95b82
https://doi.org/10.1093/ecco-jcc/jjac190.0835
https://doi.org/10.1093/ecco-jcc/jjac190.0835
Publikováno v:
Journal of Crohn's and Colitis. 17:i467-i467
Background There is increasing recognition of ‘holistic’ wellbeing as a key target in the management of IBD. Patient-reported outcomes (PROs) capture the impact of IBD on social, emotional and general wellbeing. Recently, regulatory bodies such a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc954bfe3e32c3ffed80d7548dcbbf0c
https://doi.org/10.1093/ecco-jcc/jjac190.0458
https://doi.org/10.1093/ecco-jcc/jjac190.0458
Publikováno v:
Journal of Crohn's and Colitis. 16:i399-i400
Background Infliximab (IFX) is increasingly used in the management of moderate to severe ulcerative colitis (UC) and as a ‘rescue’ treatment for acute severe UC (ASUC) but primary non response (PNR) and colectomy rates remain significant. Reasons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61fa672bb715e0dab1513c8564f65c0e
https://doi.org/10.1093/ecco-jcc/jjab232.535
https://doi.org/10.1093/ecco-jcc/jjab232.535
Publikováno v:
Journal of Crohn's and Colitis. 16:i465-i466
Background Biochemical deficiencies of iron, B12, vitamin D, vitamin K, folic acid, selenium and zinc are common in patients with Inflammatory Bowel Disease (IBD) and some micronutrient deficiencies have been associated with adverse disease outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a46f8d5ee090adc493fd9cdcaca2c5de
https://doi.org/10.1093/ecco-jcc/jjab232.631
https://doi.org/10.1093/ecco-jcc/jjab232.631
Publikováno v:
Journal of Crohn's and Colitis. 16:i474-i474
Background Exclusive enteral nutrition (EEN) is an established treatment for the induction of clinical remission in children with active Crohn’s disease (CD). However, the benefit of partial enteral nutrition (PEN), in which only some diet is repla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3673e1cb97ab0ccb7ff4c6a07019e25
https://doi.org/10.1093/ecco-jcc/jjab232.645
https://doi.org/10.1093/ecco-jcc/jjab232.645
Publikováno v:
Journal of Crohn's and Colitis. 14:S407-S407
Background Acute severe ulcerative colitis (ASUC) is a medical emergency. Rescue medical therapy is increasingly used in steroid-refractory patients but has historically been considered to delay rather than prevent colectomy. We have previously descr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7f9ed9cce12dcbab8dc5314f5302958
https://doi.org/10.1093/ecco-jcc/jjz203.585
https://doi.org/10.1093/ecco-jcc/jjz203.585